Outcomes of HLA-mismatched HSCT with TCR??/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity
| dc.contributor.author | Lum, Su Han | |
| dc.contributor.author | Albert, Michael H. | |
| dc.contributor.author | Gilbert, Patrick | |
| dc.contributor.author | Sirait, Tiarlan | |
| dc.contributor.author | Algeri, Mattia | |
| dc.contributor.author | Muratori, Rafaella | |
| dc.contributor.author | Fournier, Benjamin | |
| dc.contributor.author | Laberko, Alexandra | |
| dc.contributor.author | Karakukcu, Musa | |
| dc.contributor.author | Unal, Elrem | |
| dc.contributor.author | Ayas, Mouhab | |
| dc.contributor.author | Yadav, Satya Prakash | |
| dc.contributor.author | Fisgin, Tunc | |
| dc.contributor.author | Elfeky, Reem | |
| dc.contributor.author | Fernandes, Juliana | |
| dc.contributor.author | Faraci, Maura | |
| dc.contributor.author | Cole, Theresa | |
| dc.contributor.author | Schulz, Ansgar | |
| dc.contributor.author | Meisel, Roland | |
| dc.contributor.author | Zecca, Marco | |
| dc.contributor.author | Ifversen, Marianne | |
| dc.contributor.author | Biffi, Alessandra | |
| dc.contributor.author | Diana, Jean-Sebastien | |
| dc.contributor.author | Vallée, Tanja | |
| dc.contributor.author | Giardino, Stefano | |
| dc.contributor.author | Ersoy, Gizem Zengin | |
| dc.contributor.author | Moshous, Despina | |
| dc.contributor.author | Gennery, Andrew R. | |
| dc.contributor.author | Balashov, Dmitry | |
| dc.contributor.author | Bonfim, Carmem | |
| dc.contributor.author | Locatelli, Franco | |
| dc.contributor.author | Lankester, Arjan | |
| dc.contributor.author | Neven, Bénédicte | |
| dc.contributor.author | Slatter, Mary | |
| dc.date.accessioned | 2024-07-05T08:29:07Z | |
| dc.date.available | 2024-07-05T08:29:07Z | |
| dc.date.issued | 2024 | en_US |
| dc.department | HKÜ, Sağlık Bilimleri Fakültesi, Hemşirelik Bölümü | en_US |
| dc.description.abstract | HLA-mismatched transplants with either in vitro depletion of CD3+ T-cell receptor (TCR)αβ/CD19 (TCRαβ) cells or in vivo T-cell depletion using posttransplant cyclophosphamide (PTCY) have been increasingly used for patients with inborn errors of immunity (IEIs). We performed a retrospective multicenter study via the EBMT registry on 306 children with IEIs undergoing their first transplant between 2010 and 2019 from an HLA-mismatched donor using TCRαβ (n = 167) or PTCY (n = 139). The median age for hematopoietic stem cell transplantation (HSCT) was 1.2 years (range, 0.03-19.6 years). The 3-year overall survival (OS) was 78% (95% confidence interval (CI), 71-84) after TCRαβ and 66% (57-74) after PTCY (P = .013). Pre-HSCT morbidity score (hazard ratio [HR], 2.27; 1.07-4.80, P = .032) and non-busulfan/treosulfan conditioning (HR, 3.12; 1.98-4.92, P < .001) were the only independent predictors of unfavorable OS. The 3-year event-free survival (EFS) was 58% (50%-66%) after TCRαβ and 57% (48%-66%) after PTCY (P = .804). The cumulative incidence of severe acute graft-versus-host disease (GvHD) was higher after PTCY (15%, 9%-21%) than TCRαβ (6%, 2%-9%, P = .007), with no difference in chronic GvHD (PTCY, 11%, 6%-17%; TCRαβ, 7%, 3%-11%, P = .173). The 3-year GvHD-free EFS was 53% (44%-61%) after TCRαβ and 41% (32%-50%) after PTCY (P = .080). PTCY had significantly higher rates of veno-occlusive disease (14.4% vs TCRαβ 4.9%, P = .009), acute kidney injury (12.7% vs 4.6%, P = .032), and pulmonary complications (38.2% vs 24.1%, P = .017). Adenoviremia (18.3% vs PTCY 8.0%, P = .015), primary graft failure (10% vs 5%, P = .048), and second HSCT (17.4% vs 7.9%, P = .023) were significantly higher in TCRαβ. In conclusion, this study demonstrates that both approaches are suitable options in patients with IEIs, although they are characterized by different advantages and outcomes. © 2024 American Society of Hematology | en_US |
| dc.identifier.citation | Lum S.H., Albert M.H., Gilbert P., Sirait T., Algeri M., Muratori R., Fournier B., Unal, E. (...). (2024). Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Blood. https://doi.org/10.1182/blood.2024024038. | en_US |
| dc.identifier.doi | 10.1182/blood.2024024038 | |
| dc.identifier.issn | 00064971 | |
| dc.identifier.orcid | 0000-0002-2691-4826 | en_US |
| dc.identifier.pmid | 38669631 | |
| dc.identifier.scopus | 2-s2.0-85196417938 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://doi.org/10.1182/blood.2024024038 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.11782/4317 | |
| dc.identifier.wos | WOS:001293213800001 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | en_US |
| dc.relation.ispartof | Blood | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/restrictedAccess | en_US |
| dc.title | Outcomes of HLA-mismatched HSCT with TCR??/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity | |
| dc.type | Article |
Dosyalar
Lisans paketi
1 - 1 / 1
Yükleniyor...
- İsim:
- license.txt
- Boyut:
- 1.44 KB
- Biçim:
- Item-specific license agreed upon to submission
- Açıklama:










